Technology & Rare Neurological Diseases Symposium

TRNDS | University of Rochester

TRNDS is a national symposium on emerging novel therapeutic technologies that are creating new and rapidly expanding treatment options for patients with rare neurological disorders. TRNDS is hosted and organized by the University of Rochester, a national leader in rare disease research and therapeutic development.

Subscribe for TRNDS updates and rare disease news

September 13, 2019

7:30 am – 4:00 pm

University of Rochester
Saunders Research Building
265 Crittenden Boulevard
Rochester, NY 14620

REGISTER NOW

TRNDS | University of Rochester

Technology & Rare Neurological Diseases Symposium

Subscribe for TRNDS updates and rare disease news

September 13, 2019

7:30 am – 4:00 pm

University of Rochester
Saunders Research Building
265 Crittenden Boulevard
Rochester, NY 14620

REGISTER NOW

LEARN

Learn the latest research behind breakthrough health technologies for rare neurological disorders.

DISCOVER

Discover new ideas and innovations driving therapy development, clinical trials and clinical research.

JOIN

Join a community of renowned experts dedicated to accelerating the discovery of new therapies.

TRNDS Speakers

TRNDS 2019 speakers include leading clinical researchers, forward-thinking health technology leaders, influential patient advocates, and experts in regulatory science.

All Speakers

Erika Augustine MD, MS

TRNDS Founder & Co-Chair; Associate Director, Center for Health + Technology (CHeT), University of Rochester

Tauna Batiste MS

Executive Director, Batten Disease Support and Research Association (BDSRA)

Alison Bateman-House PhD, MPH, MA

Assistant Professor, Department of Population Health, NYU School of Medicine

Sharon Begley BA

Senior Writer, Science & Discovery, STAT News

Derek Bowen BS

VP Business Development & Strategy, Blackfynn

PJ Brooks PhD

Program Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences, NIH

Wilson Bryan MD

Director, Office of Tissues & Advanced Therapies, Center for Biologics Evaluation & Research, FDA

Mona Chitre PharmD

Chief Pharmacy Officer & Vice President Integrated Clinical Strategy & Innovation

Danielle Edwards BA

Community Engagement Manager, Jett Foundation

Emily Farkas PA-C

Patient Advocate

Tanya Fischer MD, PhD

Global Project Head, Sanofi-Genzyme

Jayne Gershkowitz BA

Chief Patient Advocate, Amicus Therapeutics

Martin Graham PhD

CEO, Empire Discovery Institute

David Jacoby MD, PhD

Vice President, Head of Clinical Science, BioMarin Pharmaceuticals

Karl Kieburtz MD, MPH

Professor of Neurology, University of Rochester Medical Center

Jinkuk Kim PhD

Research Fellow, Division of Genetics & Genomics, Harvard Medical School

Nikki Marinsek PhD

Data Scientist, Evidation Health

Rachel McMinn PhD

President & CEO, Neurogene Inc.

Elissa Orlando MPA

Strategic Liaison, Clinical & Translational Science Institute, University of Rochester Medical Center

Sean Nicholson PhD

Professor, Department of Policy Analysis & Management, Cornell University

Traci Schilling MD

Executive Director, Gene Therapy Clinical Development, PTC Therapeutics

Benjamin Schlatka MBA

CEO and Co-Founder, MC10

Scott Steele PhD

TRNDS Co-Chair; Director of Regulatory Science Programs, Clinical & Translational Science Institute (CTSI), University of Rochester

Marshall Summar MD

Director, Rare Disease Institute, Children's National Health System; Chairman of the Board, National Organization for Rare Disorders

Holly Tabor PhD

Associate Professor, Stanford University

Nancy Yu BS

Co-Founder & CEO, RDMD

Dina Zand MD

Medical Officer, Center for Drug Evaluation & Research, FDA

TRNDS Topics

The TRNDS 2019 program will focus on emerging gene therapy approaches, a new era in enzyme replacement therapy, the future of newborn screening, and novel tools and technologies contributing to the modernization of clinical research.

View Agenda